Clinical trials: Hormone-resistant Prostate Cancer
Prostate Cancer
Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer
Depending on the cohort of the study the diagnostic and prognostic accuracy and health economics considerations of [18F]-fluoro-5α-dihydrotestosterone (FDHT)- positron emission tomography (PET) and/or circulating tumor cells in…
- Trial name
- NCT05245435
- Testing
- FDHT-PET Scan, liquid biopsies
- Where
- Austria
- Sponsor
- Medical University of Vienna
Prostate Cancer
Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
This study is being conducted to determine the effectiveness of standard 3 weekly treatments using docetaxel and prednisone with metformin in patients with castration-resistant metastatic prostate cancer.
- Trial name
- NCT01478308
- Testing
- Metformin hydrochloride, Docetaxel, Prednisone
- Sponsor
- New Mexico Cancer Research Alliance
Hormone-Refractory Prostate Cancer
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
The objective of MER-101-03 is to examine the effects of two different dosing regimens of MER-101 20mg tablets versus Zometa 4mg IV infusion once-monthly therapy.
- Trial name
- NCT00636740
- Testing
- Zoledronic Acid 20mg Tablets, Zoledronic Acid
- Where
- 13 sites in United States, Estonia and 1 more
- Volunteers
- 30 people
- Sponsor
- Merrion Pharmaceuticals, LLC
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
This phase II trial is studying how well fluorine F 18 sodium fluoride positron emission tomography (PET) works in evaluating response to dasatinib in patients with prostate cancer and bone metastases.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT00936975
- Testing
- Fluorine F 18 Sodium Fluoride
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
- Trial name
- NCT00104130
- Testing
- KOS-862
- Where
- 9 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body.
- Trial name
- NCT00061126
- Testing
- ABX-EGF
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abgenix
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
ACCEL is a multicenter, open label phase Ia/Ib/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer
- Trial name
- ACCEL (NCT06229366)
- Testing
- [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC)
- Where
- 7 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Prostatic Neoplasms
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with…
- Trial name
- NCT01618370
- Testing
- Radium-223 dichloride (BAY88-8223)
- Where
- 215 sites in Belgium, Canada and 17 more
- Volunteers
- 705 people
- Sponsor
- Bayer
Breast Cancer, Insulin Resistance
Alternative Physical Activity Strategies for Breast Cancer Survivors
The primary aim of this study is to compare the acute glycemic effects of two novel, alternative physical activity (PA) strategies (dispersed post-meal PA, PA snacks) to a no PA condition and to exercise sessions representing the…
- Conditions
- Breast Cancer, Insulin Resistance, Cardiometabolic Risk Factors
- Trial name
- PACE (NCT06633380)
- Testing
- Standard Physical Activity - Fasted, Standard Physical Activity - Post-Meal, Dispersed Physical Activity
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Bone Neoplasms
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(ONJ), overall safety and skeletal related events…
- Trial name
- NCT00434447
- Testing
- Zoledronic acid
- Where
- 10 sites in Australia
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Castrate Resistant Prostate Cancer, Prostate Cancer
PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy
One purpose of this research study is to examine if a special type of imaging test, a positron emission tomography (PET) scan using the radioactive material [C-11] acetate, will be helpful in detecting prostate cancer lesions in…
- Trial name
- NCT01144897
- Testing
- PET Acetate scan, Carbon-11 labeled Acetate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Daniel Vaena
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01812668
- Testing
- cabozantinib-s-malate, fluorine F 18 d-FMAU, positron emission tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00054574
- Testing
- panitumumab
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
Metastatic Prostate Cancer
INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)
To determine if supervised high intensity aerobic and resistance training increases overall survival compared to self-directed exercise in patients with metastatic prostate cancer.
- Trial name
- INTERVAL (NCT02730338)
- Testing
- High intensity aerobic and resistance training, Psychosocial support
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 866 people
- Sponsor
- Movember Foundation
Metastatic Castration Resistant Prostate Cancer
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or…
- Trial name
- Himalayas-1 (NCT07723248)
- Testing
- Rinzimetostat, Darolutamide, Enzalutamide
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- ORIC Pharmaceuticals
Metastatic Prostate Cancer
Exploiting Heterogeneity in Hormone Therapy Response to Reveal Early Determinants of Drug Resistance in Advanced PCa
The goal of this observational study is to study intra-patient tumor and TME heterogeneity after initiation of hormonal therapy (ADT +- ARSI), while the patient is responding to treatment, to understand the drivers of hormonal…
- Trial name
- MOSAIC (NCT07352748)
- Testing
- biopsy, Prostate biopsy
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Universita di Verona
Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide.
- Conditions
- Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT03016741
- Testing
- GnRH agonist/antagonist, Prednisone, Abiraterone Acetate
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Northwestern University
Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in combination with enzalutamide.
- Trial name
- NCT06702995
- Testing
- XNW5004, enzalutamide
- Where
- 2 sites in China
- Volunteers
- 307 people
- Sponsor
- Evopoint Biosciences Inc.
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01533246
- Testing
- linsitinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)